Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Capital Expenditures: 2017-2024

Historic Capital Expenditures for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to $25,000.

  • DiaMedica Therapeutics' Capital Expenditures rose 207.69% to $14,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $32,000, marking a year-over-year decrease of 36.00%. This contributed to the annual value of $25,000 for FY2024, which is 4.17% up from last year.
  • Per DiaMedica Therapeutics' latest filing, its Capital Expenditures stood at $25,000 for FY2024, which was up 4.17% from $24,000 recorded in FY2023.
  • DiaMedica Therapeutics' Capital Expenditures' 5-year high stood at $81,000 during FY2022, with a 5-year trough of $22,000 in FY2021.
  • Its 3-year average for Capital Expenditures is $43,333, with a median of $25,000 in 2024.
  • As far as peak fluctuations go, DiaMedica Therapeutics' Capital Expenditures spiked by 2,250.00% in 2020, and later plummeted by 70.37% in 2023.
  • Yearly analysis of 5 years shows DiaMedica Therapeutics' Capital Expenditures stood at $47,000 in 2020, then slumped by 53.19% to $22,000 in 2021, then skyrocketed by 268.18% to $81,000 in 2022, then plummeted by 70.37% to $24,000 in 2023, then increased by 4.17% to $25,000 in 2024.